Insurance reimbursement and coverage risk
The SmartVest System often relies on Medicare, Medicaid, HMOs, and private payer approval for adoption.
- Scope
- Homecare sales and patient conversion
- Materiality
- high
Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy systems used to help patients with compromised pulmonary function clear mucus and breathe more easily. Its core product is the SmartVest® Airway Clearance System, sold mainly through a direct-to-patient and provider model that works with clinicians, manages insurance reimbursement, and delivers devices for home use, with additional sales into hospitals and selected international markets.
20,0 %
78,5 %
15,3 %
+15,3 %
4.69
4.39
| % | |
|---|---|
| Airway clearance systems | 88% HFCWO devices that help mobilize secretions and improve bronchial drainage. |
| Homecare services and support | 7% Patient onboarding, training, insurance claims support, and direct fulfillment for home use. |
| Hospital and acute-care sales | 5% Device sales for inpatient, post-surgical, ICU, and respiratory therapy settings. |
Electromed sells primarily to patients with physician prescriptions, but the buying process is driven by...
- Homecare patients with pulmonary diseaseprimary
Patients with bronchiectasis, cystic fibrosis, COPD-related bronchiectasis, and chronic pulmonary conditions who use SmartVest at home because it is prescribed, reimbursable, and supported by direct delivery and training.
- Neuromuscular disease patientsprimary
Patients with ALS, cerebral palsy, muscular dystrophies, and similar conditions who need airway clearance to manage retained secretions and reduce respiratory complications.
- Pulmonologists and referring cliniciansprimary
Specialists and clinic staff who identify eligible patients, prescribe therapy, and influence adoption through clinical confidence and referral patterns.
- Hospitals and acute-care institutionssecondary
Hospitals, rental companies, and other institutions purchasing HFCWO systems for inpatient, post-surgical, ICU, or infection-related respiratory support.
- HME and respiratory therapy distributorssecondary
Limited distribution partners that extend reach in the U.S. homecare market and support incremental sales volume.
Electromed is primarily a U.S. business, and management says most revenue comes from domestic homecare sales through...
- •U.S. is the core market and the main source of revenue
- •Domestic homecare is the largest channel and depends on referrals
- •U.S. hospital sales add a smaller acute-care revenue stream
- •Select international countries are served through approvals and distributors
- •International distributor demand is smaller and more volatile
Electromed is focused on expanding its direct sales force, increasing awareness of HFCWO therapy, and growing share in...
01
Expand the direct sales forceshort-term
More territories and reps should increase referrals, approvals, and homecare conversions.
02
Increase share in adult pulmonology and bronchiectasismedium-term
This is described as the largest and fastest-growing addressable segment.
03
Improve product innovation and patient experiencemedium-term
Better usability and comfort can support conversion, retention, and clinician preference.
Electromed depends on physician referrals, insurance reimbursement, and continued clinical acceptance of HFCWO therapy,...
Physician referral and clinical adoption risk
The direct-to-patient model depends on pulmonologists and clinicians prescribing therapy and supporting referrals.
- Scope
- Core domestic revenue engine
- Materiality
- high
Regulatory and product clearance risk
The company depends on FDA clearance and ongoing compliance for marketed devices.
- Scope
- Product portfolio and future launches
- Materiality
- high
Hospital capital spending cyclicality
Hospital revenue can fluctuate with capital budget allocations and long sales cycles.
- Scope
- Hospital and acute-care segment
- Materiality
- medium
Channel mix and distributor execution risk
Limited HME and international distributor sales can be uneven and depend on partner performance.
- Scope
- Homecare distributor and other revenue
- Materiality
- medium
Revenue recognition
Affects reported revenue by channel and quarterly comparability
Quarterly seasonality and lumpy hospital demand
Can distort near-term growth rates and margin trends
Share-based compensation valuation
Affects SG&A and diluted earnings
: 28.4.2026